MedTrace Logo

Amivantamab in Adenoid Cystic Carcinoma

NCT05074940 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2026-05-08

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.

Conditions

  • Salivary Gland Cancer

Interventions

DRUG

Amivantamab

Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).

Sponsors & Collaborators

  • Trisha Wise-Draper

    lead OTHER

Principal Investigators

  • Trisha Wise-Draper, MD, PhD · University of Cincinnati

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-05
Primary Completion
2026-03-02
Completion
2028-08-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05074940 on ClinicalTrials.gov